Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SINOPEC CORP
00386
5
CNOOC
00883
No Data
Mayne Pharma Releases Investor Presentation on 3Q FY26 Results
Mayne Pharma Performance Rights Lapse Reduces Potential Equity Dilution
Mayne Pharma Details Equity Incentives for New CEO Aaron Gray
Mayne Pharma Group Reports Higher Fiscal Q3 Revenue
Mayne Pharma Posts Strong Cash Flow and Momentum in Women's Health on 3Q FY26 Update
Mayne Pharma Group Expects No Material Impact From New US Pharmaceutical Tariffs; Shares Rise 3%